Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease

from The Long Run with Luke Timmerman · host Timmerman Report

Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).

Episode metadata supplied by the publisher feed · Published Dec 15, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease

0:00 1:07:34

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Long Run with Luke Timmerman?

This episode is 1 hour and 7 minutes long.

When was this The Long Run with Luke Timmerman episode published?

This episode was published on December 15, 2025.

Can I download this The Long Run with Luke Timmerman episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!